SG11201911838UA - Chimeric antigen receptors with mutated cd28 costimulatory domains - Google Patents

Chimeric antigen receptors with mutated cd28 costimulatory domains

Info

Publication number: SG11201911838UA
Authority: SG; Singapore
Prior art keywords: mutated; chimeric antigen; antigen receptors; costimulatory domains; costimulatory
Prior art date: 2017-07-07

Application number

SG11201911838UA

Inventor

Marco L Davila

Original Assignee

H Lee Moffitt Cancer Center And Research Institute Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-07-07

Filing date

2018-07-06

Publication date

2020-01-30

2018-07-06 Application filed by H Lee Moffitt Cancer Center And Research Institute Inc filed Critical H Lee Moffitt Cancer Center And Research Institute Inc

2020-01-30 Publication of SG11201911838UA publication Critical patent/SG11201911838UA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

SG11201911838UA 2017-07-07 2018-07-06 Chimeric antigen receptors with mutated cd28 costimulatory domains SG11201911838UA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762529919P	2017-07-07	2017-07-07
PCT/US2018/041040 WO2019010383A1 (en)	2017-07-07	2018-07-06	Chimeric antigen receptors with mutated cd28 costimulatory domains

Publications (1)

Publication Number	Publication Date
SG11201911838UA true SG11201911838UA (en)	2020-01-30

Family

ID=64950396

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201911838UA SG11201911838UA (en)	2017-07-07	2018-07-06	Chimeric antigen receptors with mutated cd28 costimulatory domains

Country Status (11)

Country	Link
US (1)	US12065474B2 (en)
EP (1)	EP3648799A4 (en)
JP (1)	JP7141725B2 (en)
KR (1)	KR20200027508A (en)
CN (1)	CN111212663A (en)
AU (1)	AU2018297318B2 (en)
BR (1)	BR112020000118A2 (en)
CA (1)	CA3067605A1 (en)
MX (1)	MX2019015484A (en)
SG (1)	SG11201911838UA (en)
WO (1)	WO2019010383A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3044593A1 (en)	2016-11-22	2018-05-31	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
US20210079061A1 (en) *	2018-02-26	2021-03-18	Fred Hutchinson Cancer Research Center	Compositions and methods for cellular immunotherapy
MX2021002702A (en)	2018-09-10	2021-05-12	Atara Biotherapeutics Inc	METHODS FOR EXPANDING ANTIGEN-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELLS, COMPOSITIONS AND USES RELATED THEREOF.
WO2020160419A1 (en) *	2019-02-01	2020-08-06	The Trustees Of Dartmouth College	Signaling platforms for chimeric antigen receptor t cells
MX2021013368A (en) *	2019-04-30	2021-11-25	Atara Biotherapeutics Inc	T CELLS OF THE RECEPTOR OF CHIMERIC ANTIGENS FOCUSED TO CD19 SPECIFIC OF THE ANTIGEN.
SG11202111130SA (en)	2019-04-30	2021-11-29	Senti Biosciences Inc	Chimeric receptors and methods of use thereof
CN110256582B (en) *	2019-07-10	2021-09-17	杭州普科亭生物医药有限公司	Chimeric antigen receptor comprising CD28 and 4-1BB and uses thereof
AU2021216450A1 (en) *	2020-02-05	2022-09-08	Memorial Sloan-Kettering Cancer Center	Chimeric antigen receptors with CD28 mutations and use thereof
US20230257477A1 (en) *	2020-07-02	2023-08-17	H. Lee Moffitt Cancer Center And Research Institute Inc.	Dual chimeric antigen receptor t cells targeting ccd99- and clec12a-expressing cancers
US20220235114A1 (en) *	2021-01-27	2022-07-28	H.Lee Moffitt Cancer Center And Research Institute, Inc.	Chimeric antigen receptors with mutated cd28 costimulatory domains
AU2022257812A1 (en) *	2021-04-12	2023-10-12	Medgene Therapeutics, Inc.	Method for activating and proliferating cd8 t cells exposed to antigen, cd8 t cells, prepared thereby, having enhanced anticancer activity, and use thereof
EP4613781A1 (en) *	2022-12-01	2025-09-10	Nanjing Bioheng Biotech Co., Ltd	Immune rejection-resistant engineered cell
CN116286660B (en) *	2022-12-08	2023-10-03	全球细胞控股(广州)有限公司	IPSC- (CAR) natural killer cells, preparation method and application thereof in tumor treatment
WO2025038602A1 (en) *	2023-08-14	2025-02-20	Ginkgo Bioworks, Inc.	Immune cell stimulatory sequences
CN119930792A (en) *	2023-11-02	2025-05-06	重庆精准生物技术有限公司	Specific TIGIT peptide

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3456099A (en)	1998-03-31	1999-10-18	Geron Corporation	Methods and compositions for eliciting an immune response to a telomerase antigen
US6713055B2 (en)	2000-11-27	2004-03-30	Geron Corporation	Glycosyltransferase vectors for treating cancer
PT1836225E (en)	2005-01-06	2012-01-10	Novo Nordisk As	Kir-binding agents and methods of use thereof
PL2161336T5 (en)	2005-05-09	2017-10-31	Ono Pharmaceutical Co	Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US9334330B2 (en)	2006-10-10	2016-05-10	Universite De Nantes	Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers
CA2998281C (en)	2008-09-26	2022-08-16	Dana-Farber Cancer Institute, Inc.	Human anti-pd-1 antobodies and uses therefor
KR101050829B1 (en)	2008-10-02	2011-07-20	서울대학교산학협력단	Anticancer agents comprising an anti-PD-1 antibody or an anti-PD-L1 antibody
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
BR112015027567B1 (en) *	2013-05-03	2024-02-20	Ohio State Innovation Foundation	POLYPEPTIDE, ISOLATED NUCLEIC ACID SEQUENCE, VECTOR, METHOD OF OBTAINING CELL, USE OF A CELL
CN104462128B (en)	2013-09-22	2018-04-13	腾讯科技（深圳）有限公司	The method, apparatus and terminal device of multimedia file processing
JP6772063B2 (en) *	2014-02-14	2020-10-21	ベリカムファーマシューティカルズ，インコーポレイテッド	Methods for activating cells using inducible chimeric polypeptides
EP3172237A2 (en) *	2014-07-21	2017-05-31	Novartis AG	Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016179319A1 (en) *	2015-05-04	2016-11-10	Cellerant Therapeutics, Inc.	Chimeric antigen receptors with ctla4 signal transduction domains
EP4043485A1 (en) *	2017-01-26	2022-08-17	Novartis AG	Cd28 compositions and methods for chimeric antigen receptor therapy
US11434290B2 (en) *	2017-06-08	2022-09-06	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Chimeric antigen receptors with enhanced NFκB signaling
US20230265184A1 (en) *	2017-12-11	2023-08-24	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Chimeric antigen receptors with enhanced nfkb signaling
WO2019178463A1 (en) *	2018-03-16	2019-09-19	H. Lee Moffitt Cancer Center And Research Institute Inc.	Chimeric antigen receptors with mutated cd28 phosphorylation sites

2018
- 2018-07-06 SG SG11201911838UA patent/SG11201911838UA/en unknown
- 2018-07-06 JP JP2019571984A patent/JP7141725B2/en active Active
- 2018-07-06 EP EP18828264.4A patent/EP3648799A4/en active Pending
- 2018-07-06 WO PCT/US2018/041040 patent/WO2019010383A1/en not_active Ceased
- 2018-07-06 AU AU2018297318A patent/AU2018297318B2/en active Active
- 2018-07-06 CA CA3067605A patent/CA3067605A1/en active Pending
- 2018-07-06 KR KR1020207001579A patent/KR20200027508A/en not_active Abandoned
- 2018-07-06 CN CN201880045582.1A patent/CN111212663A/en active Pending
- 2018-07-06 MX MX2019015484A patent/MX2019015484A/en unknown
- 2018-07-06 US US16/629,046 patent/US12065474B2/en active Active
- 2018-07-06 BR BR112020000118-0A patent/BR112020000118A2/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO2019010383A1 (en)	2019-01-10
EP3648799A1 (en)	2020-05-13
US20200129554A1 (en)	2020-04-30
CN111212663A (en)	2020-05-29
JP2020530269A (en)	2020-10-22
KR20200027508A (en)	2020-03-12
RU2020104792A3 (en)	2021-11-02
EP3648799A4 (en)	2021-06-02
AU2018297318A1 (en)	2020-01-02
MX2019015484A (en)	2020-07-28
BR112020000118A2 (en)	2020-07-07
US12065474B2 (en)	2024-08-20
CA3067605A1 (en)	2019-01-10
JP7141725B2 (en)	2022-09-26
RU2020104792A (en)	2021-08-03
AU2018297318B2 (en)	2025-05-08

Publication	Publication Date	Title
SG11201911838UA (en)	2020-01-30	Chimeric antigen receptors with mutated cd28 costimulatory domains
HUS2500051I1 (en)	2025-12-28	Humanized or chimeric cd3 antibodies
IL274921A (en)	2020-07-30	Bcma-targeting chimeric antigen receptor, and uses thereof
SG11202100205UA (en)	2021-02-25	Ror-1 specific chimeric antigen receptors and uses thereof
IL263626A (en)	2019-01-31	Chimeric antigen receptors and methods for use
SG11201701297WA (en)	2017-03-30	Antibodies and chimeric antigen receptors specific for cd19
IL257138A (en)	2018-03-29	Chimeric antigen receptors with integrated controllable functions
SG11202102781UA (en)	2021-04-29	Chimeric antigen receptor
GB201607968D0 (en)	2016-06-22	Chimeric antigen receptor
GB201610512D0 (en)	2016-08-03	Chimeric antigen receptor
EP3119425A4 (en)	2017-11-22	Regulatable chimeric antigen receptor
SG11201606790XA (en)	2016-09-29	Chimeric antigen receptor
ZA201906321B (en)	2021-02-24	Chimeric antigen receptor
ZA202005837B (en)	2023-02-22	Cd83-binding chimeric antigen receptors
GB201709508D0 (en)	2017-08-02	Chimeric antigen receptor
IL266950B1 (en)	2023-09-01	Γδ τ cells that express chimeric antigen receptor for use in immunotherapy
GB201807862D0 (en)	2018-06-27	Chimeric antigen receptor
GB2585607B (en)	2022-09-07	Chimeric antigen receptor and application thereof
GB201721421D0 (en)	2018-01-31	Chimeric antigen receptor
GB201815775D0 (en)	2018-11-14	Chimeric antigen receptor
GB201809773D0 (en)	2018-08-01	Chimeric antigen receptor
GB201807866D0 (en)	2018-06-27	Chimeric antigen receptor
HK40034354A (en)	2021-04-23	Pd1-specific chimeric antigen receptor as an immunotherapy
HK40013263A (en)	2020-08-07	Chimeric antigen receptor
HK40010117A (en)	2020-07-03	Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof